SPTX — Seaport Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Seaport Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -46.9 | -74.9 |
| Depreciation | ||
| Non-Cash Items | 14.6 | 4.7 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 2.51 | -7.93 |
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Cash from Operating Activities | -29.6 | -77.9 |
| Capital Expenditures | -0.113 | -0.356 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 0 | -184 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | -0.113 | -184 |
| Financing Cash Flow Items | 13.2 | -0.874 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Cash from Financing Activities | 339 | -0.873 |
| Foreign Exchange Effects | ||
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 310 | -263 |